Biohaven Ltd. Other Noncash Income (Expense)
Biohaven Ltd. (BHVN) reported Other Noncash Income (Expense) of $1.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-10
- Biohaven Ltd. other noncash income (expense) for the quarter ending 2026-06-30 was $520.00K, a 62.94% decline year-over-year.
- Biohaven Ltd. other noncash income (expense) for the quarter ending 2026-03-31 was $837.00K, a 70.57% decline year-over-year.
- Biohaven Ltd. other noncash income (expense) for the quarter ending 2025-12-31 was -$5.58M, a 212.72% decline year-over-year.
- Biohaven Ltd. other noncash income (expense) for the quarter ending 2025-09-30 was $1.16M, a 67.90% decline year-over-year.
- Biohaven Ltd. other noncash income (expense) for fiscal 2025 was -$174.00K, a 101.49% decline from fiscal 2024.
- Biohaven Ltd. other noncash income (expense) for fiscal 2024 was $11.70M, a 105.91% increase from fiscal 2023.
- Biohaven Ltd. other noncash income (expense) for fiscal 2023 was $5.68M.
- Biohaven Ltd. other noncash income (expense) for fiscal 2022 was -$726.00K, a 121.30% decline from fiscal 2021.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $520.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.36M 10-Q · filed 2026-08-10 | -$4.23M derived: sum of 3 quarters · filed 2026-08-10 | -$3.06M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $837.00K 10-Q · filed 2026-05-04 | -$4.75M derived: sum of 2 quarters · filed 2026-05-04 | -$3.58M derived: sum of 3 quarters · filed 2026-05-04 | -$2.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$4.42M derived: sum of 2 quarters · filed 2026-03-02 | -$3.02M derived: sum of 3 quarters · filed 2026-08-10 | -$174.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.56M derived: sum of 2 quarters · filed 2026-08-10 | $5.41M 10-Q · filed 2025-11-10 | $10.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.25M 10-Q · filed 2026-08-10 | $9.20M derived: sum of 3 quarters · filed 2026-08-10 | $12.82M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.84M 10-Q · filed 2026-05-04 | $7.80M derived: sum of 2 quarters · filed 2026-05-04 | $11.42M derived: sum of 3 quarters · filed 2026-05-04 | $13.49M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.57M derived: sum of 2 quarters · filed 2026-03-02 | $10.64M derived: sum of 3 quarters · filed 2026-03-02 | $11.70M 10-K · filed 2026-03-02 |
| 2024-09-30 | $3.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $5.69M derived: sum of 2 quarters · filed 2025-11-10 | $6.75M 10-Q · filed 2025-11-10 | $7.74M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $3.13M 10-Q · filed 2025-08-11 | $4.12M derived: sum of 3 quarters · filed 2026-03-02 | $5.13M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $1.06M 10-Q · filed 2025-05-12 | $2.04M derived: sum of 2 quarters · filed 2026-03-02 | $3.06M derived: sum of 3 quarters · filed 2026-03-02 | $5.00M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $987.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.00M derived: sum of 2 quarters · filed 2026-03-02 | $3.94M derived: sum of 3 quarters · filed 2026-03-02 | $5.68M 10-K · filed 2026-03-02 |
| 2023-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.95M derived: sum of 2 quarters · filed 2024-11-12 | $4.70M 10-Q · filed 2024-11-12 | $3.97M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $3.68M 10-Q · filed 2024-08-09 | $2.96M derived: sum of 3 quarters · filed 2025-03-03 | $2.96M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $1.75M 10-Q · filed 2024-05-09 | $1.02M derived: sum of 2 quarters · filed 2025-03-03 | $1.02M derived: sum of 3 quarters · filed 2025-03-03 | $770.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$726.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$726.00K derived: sum of 2 quarters · filed 2025-03-03 | -$976.00K derived: sum of 3 quarters · filed 2025-03-03 | -$726.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$250.00K derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | $1.46M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $0.00 10-Q · filed 2023-07-31 | $1.46M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2022-03-31 | $250.00K 10-Q · filed 2023-05-12 | $1.71M derived: sum of 2 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.41M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $1.95M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |